Browse by Title

Type here to filter the list

A
A brief history of model-informed discovery and development of advanced therapies
Favorite

Piet van der Graaf, PharmD, PhD – Certara ### 2360684###Speaker###Senior Vice President###Certara###
Speaker: Piet van der Graaf, PharmD, PhD – Certara
###
A mechanistic model to inform step-up dosing that limits cytokine release following a bispecific T cell engaging antibody treatment for B-cell lymphomas
Favorite

Vincent Hurez, DVM, PhD (he/him/his) – Regeneron Pharmaceuticals Inc. ### 2487145###Speaker###Director Group Quantitative Pharmacology###Regeneron Pharmaceuticals Inc.###
Speaker: Vincent Hurez, DVM, PhD (he/him/his) – Regeneron Pharmaceuticals Inc.
### he/him/his
A streamlined QSP workflow for digital-twin enabled in silico trials with chronic Hepatitis B infection
Favorite

Rajat Desikan, PhD (he/him/his) – Clinical Pharmacology Modelling & Simulation – Vaccines & Infectious Diseases, Precision Medicine, GSK ### 2360727###Speaker###Director###Clinical Pharmacology Modelling & Simulation – Vaccines & Infectious Diseases, Precision Medicine, GSK###
Speaker: Rajat Desikan, PhD (he/him/his) – Clinical Pharmacology Modelling & Simulation – Vaccines & Infectious Diseases, Precision Medicine, GSK
### he/him/his
ACoP 2024 Meets ACoP 2025 (invite only)
Favorite
ACoP 2024 Opening Session
Favorite

Wei Gao, PhD – Moderna ### 2407515###Speaker###Head of Clinical Pharmacology and Pharmacometrics###Moderna###
Speaker: Wei Gao, PhD – Moderna
### @@@ Nahor Haddish-Berhane ### 2407516###Speaker#########
Speaker: Nahor Haddish-Berhane
###
ACoP Preconference - Exploring New Frontiers: Quantitative Pharmacology for Emerging Therapeutic Modalities - Welcome, Introduction & Problem Statement
Favorite

Joy C. Hsu, PhD – Genentech ### 2360676###Co-Chair###Director, Clinical Pharmacology and Pharmacometrics###Genentech###
Co-Chair: Joy C. Hsu, PhD – Genentech
### @@@ Mark Lovern, PhD (he/him/his) – InSilicoTrials ### 2343536###Co-Chair###Chief Platform Officer###InSilicoTrials###
Co-Chair: Mark Lovern, PhD (he/him/his) – InSilicoTrials
### he/him/his
ACoP Special Session-The Future is Now: Envisioning the Next Era of Pharmacometrics
Favorite

Lora Hamuro ### 2501748###Chair#########
Chair: Lora Hamuro
### @@@ Stephen Greene ### 2501749###Chair#########
Chair: Stephen Greene
### @@@ Hao Zhu, PhD – ISoP ### 2360688###Panelist###ISoP Board Member###ISoP###
Panelist: Hao Zhu, PhD – ISoP
### @@@ C.J. Musante, PhD – Pfizer ### 2407910###Panelist###VP & Global Head of Pharmacometrics & Systems Pharmacology###Pfizer###
Panelist: C.J. Musante, PhD – Pfizer
### @@@ Mark Dresser (he/him/his) – Gilead Sciences ### 2501751###Panelist###Senior Vice President###Gilead Sciences###
Panelist: Mark Dresser (he/him/his) – Gilead Sciences
### he/him/his @@@ Liang Zhao, PhD (he/him/his) – Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, UCSF ### 2360729###Panelist###Professor###Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, UCSF###
Panelist: Liang Zhao, PhD (he/him/his) – Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, UCSF
### he/him/his
Advancing Artificial Intelligence (AI) tools for drug R&D
Favorite

Liang Zhao, PhD (he/him/his) – Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, UCSF ### 2360729###Speaker###Professor###Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, UCSF###
Speaker: Liang Zhao, PhD (he/him/his) – Department of Bioengineering and Therapeutic Sciences, School of Pharmacy, UCSF
### he/him/his
Advancing Drug Development through Model Informed Drug Development: Insights from the ICH M15 MIDD Guidance Working Group
Favorite

Jenny Chien, PhD – Eli Lilly and Company ### 2360687###Speaker###Associate Vice President###Eli Lilly and Company###
Speaker: Jenny Chien, PhD – Eli Lilly and Company
###
Advancing QSP: From Virtual Patient To Digital Twin
Favorite

Jingqi Gong, PhD (she/her/hers) – GlaxoSmithKline ### 2360666###Chair###Associate Director, Quantitative Systems Pharmacology###GlaxoSmithKline###
Chair: Jingqi Gong, PhD (she/her/hers) – GlaxoSmithKline
### she/her/hers @@@ Richard Allen, PhD – Pfizer ### 2360668###Speaker###Research Fellow and Quantitative Systems Pharmacology Lead###Pfizer###
Speaker: Richard Allen, PhD – Pfizer
### @@@ Oleg Demin Jr (he/him/his) – InSysBio CY ### 2360667###Both###Scientific Director, Oncology & Immuno-Oncology Quantitative Systems Pharmacology###InSysBio CY###
Both: Oleg Demin Jr (he/him/his) – InSysBio CY
### he/him/his @@@ Susana Zaph, PhD (she/her/hers) – Sanofi ### 2360669###Speaker###Senior Director & Head of Translational Disease Modeling - US###Sanofi###
Speaker: Susana Zaph, PhD (she/her/hers) – Sanofi
### she/her/hers
AI-aided Virtual Disease Progression Clinical trials – the marriage of nonlinear mathematical modeling, biology, and AI in predicting future individual patient responses in global health
Favorite

Tawanda Gumbo, MD (he/him/his) – CEO, Phase Advance AI ### 2380003###Speaker###Professor of Medicine###CEO, Phase Advance AI###
Speaker: Tawanda Gumbo, MD (he/him/his) – CEO, Phase Advance AI
### he/him/his
Application of endogenous biomarkers of drug transporters and liquid biopsy coupled with PBPK modelling to support precision dosing in renal impairment
Favorite

Aleksandra Galetin, PhD (she/her/hers) – University of Manchester ### 2379986###Speaker###Professor of Translational Pharmacokinetics ###University of Manchester###
Speaker: Aleksandra Galetin, PhD (she/her/hers) – University of Manchester
### she/her/hers
Application of endogenous biomarkers of drug transporters and liquid biopsy coupled with PBPK modelling to support precision dosing in renal impairment
Favorite

Aleksandra Galetin, PhD (she/her/hers) – University of Manchester ### 2379986###Speaker###Professor of Translational Pharmacokinetics ###University of Manchester###
Speaker: Aleksandra Galetin, PhD (she/her/hers) – University of Manchester
### she/her/hers
Applications of A Platform PBPK Model of Antisense Oligonucleotides Towards Candidate Selection, Tox Study Design and Human Dose Projection
Favorite

Samira Khalili (she/her/hers) – Ionis ### 2363741###Speaker###Director of Pharmacokinetics and Clinical Pharmacology###Ionis###
Speaker: Samira Khalili (she/her/hers) – Ionis
### she/her/hers
Applying Bayesian Methods for Dose Optimization in Pediatric Oncology: Leveraging from Adult Population Pharmacokinetics
Favorite

Nastya Kassir, PharmD, PhD, FCP (she/her/hers) – Genentech ### 2343528###Speaker###Senior Director & Distinguished Scientist###Genentech###
Speaker: Nastya Kassir, PharmD, PhD, FCP (she/her/hers) – Genentech
### she/her/hers